TSE:2802Food
Can Ajinomoto’s (TSE:2802) Buyback and Biotech Deal Reveal a Strategic Shift in Value Creation?
Ajinomoto Co., Inc. recently announced a share repurchase program of up to 30,000,000 shares for ¥80,000 million and entered a licensing agreement with Astellas Pharma Inc. for its proprietary AJICAP antibody-drug conjugate technology.
This collaboration extends Ajinomoto's reach in the growing biopharmaceutical sector and highlights its strategic focus on health-related technology and shareholder returns.
We’ll now examine how the new share buyback plan could influence Ajinomoto’s...